BCRX / BioCryst Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

As filed with the Securities and Exchange Commission on August 12, 2025

As filed with the Securities and Exchange Commission on August 12, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 BIOCRYST PHARMACEUTICALS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23186 BIO

Amendment No. 2 to the Employment Agreement, effective August 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and Charles Gayer.

Exhibit 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”), dated August 1, 2025 (the “Effective Date”), is entered into by and between BioCryst Pharmaceuticals, Inc. (the “Company”) and Mr. Charles Gayer (“Employee”). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of January 14, 2020, as ame

Amended and Restated Employment Agreement, effective July 23, 2025, by and between BioCryst Pharmaceuticals, Inc. and Babar Ghias.

Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Amendment”) is made effective as of the 23rd day of July, 2025, between Babar Ghias (“Employee”), and BioCryst Pharmaceuticals, Inc., a Delaware corporation, located at 4505 Emperor Boulevard, Suite 200, Durham NC 27703 (“Company”). The parties agree that any and all actions by a party pursuant

May 31, 2025, by and between BioCryst Pharmaceuticals, Inc. and

Exhibit 10.2 AMENDMENT TO CONSULTING AGREEMENT THIS FIRST AMENDMENT to the CONSULTING AGREEMENT (the “First Amendment”) is made and entered into on this 31st day of May, 2025 (the “First Amendment Effective Date”), by and between BioCryst Pharmaceuticals, Inc., a Delaware Corporation and Anthony Doyle RECITALS WHEREAS, BioCryst and Anthony Doyle entered into a Consulting Agreement (the “Agreement”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57

EXHIBIT 99.1 BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt w

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

EXHIBIT 99.1 BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

EXHIBIT 99.1 BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 BioCryst Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commis

Stock Purchase Agreement, dated as of June 27, 2025, by and among BioCryst Pharmaceuticals, Inc., BioCryst Ireland Limited and Neopharmed Gentili S.p.A.*

Exhibit 2.1 EXECUTION VERSION STOCK PURCHASE AGREEMENT dated as of June 27, 2025 by and among BIOCRYST PHARMACEUTICALS, INC., as the Seller, BIOCRYST IRELAND LIMITED, as the Company, and NEOPHARMED GENTILI S.P.A., as the Purchaser TABLE OF CONTENTS Page Article I DEFINITIONS Section 1.1 Definitions 1 Article II PURCHASE AND SALE; CLOSING Section 2.1 Purchase and Sale 18 Section 2.2 Closing Purchas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 millio

EXHIBIT 99.1 BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commissio

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 21, 2025).

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 21, 2025) ARTICLE One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,” is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), by provi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commis

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years –FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO w

EXHIBIT 99.1 BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years –FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of 12, if approved– RESEARCH TRIANGLE PARK, N.C.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BioCryst Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23186 BI

BioCryst Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy, effective April 21, 2025

Exhibit 10.3 BIOCRYST PHARMACEUTICALS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective April 21, 2025 Each member of the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each a “Director”) will, automatically and without further action by the Board or th

Form of Notice of Grant of Stock Option and Standard Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan

Exhibit 10.2 BIOCRYST PHARMACEUTICALS, INC. NOTICE OF GRANT OF STOCK OPTION Notice is hereby given of the following stock option grant (the “Option”) to purchase shares of the Common Stock of BioCryst Pharmaceuticals, Inc. (the “Company”): Optionee: Grant Date: Option Price: Number of Optioned Shares: Expiration Date: Type of Option: Incentive Stock Option (up to tax code limits – the portion of t

BioCryst Pharmaceuticals, Inc

Exhibit 10.1 CONSULTING AGREEMENT This CONSULTING AGREEMENT (the “Agreement”) is hereby entered into by and between Anthony Doyle (“Consultant”) with an address at 317 Cypress Falls Drive, Cary, NC 27513 and BioCryst Pharmaceuticals, Inc. (together with its Affiliates, “BioCryst”) a Delaware corporation, with offices at 4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703 and shall be e

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now

EXHIBIT 99.1 BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BioCryst Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commiss

BioCryst Appoints Steve Frank to Board of Directors

EXHIBIT 99.1 BioCryst Appoints Steve Frank to Board of Directors RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously gl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Emp

, 2025, by and between BioCryst UK Limited and BioPharma Credit PLC.

Exhibit 10.50 JOINDER AGREEMENT This JOINDER AGREEMENT, dated as of February 24, 2025, is delivered in connection with Sections 5.12 and 5.13 of the Loan Agreement, dated as of April 17, 2023, by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), and the other Persons from time to time party thereto as Grantors or Guarantors, in favor of BIOPHARMA CREDIT PLC (together w

BioCryst Pharmaceuticals, Inc. I

Exhibit 19 BIOCRYST PHARMACEUTICALS, INC. Insider Trading Policy 1.0 PURPOSE 1.1 BioCryst Pharmaceuticals, Inc. (the “Company”) has adopted this Insider Trading Policy (the “policy”), which provides guidelines for trading in Company and other securities, in order to comply with federal and state securities laws governing trading in securities while aware of material nonpublic information, as well

Subsidiaries of the Registrant.

Exhibit 21 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation BioCryst Canada, ULC British Columbia BioCryst España S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PH

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net rev

EXHIBIT 99.1 BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 mil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Empl

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) —ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between

EXHIBIT 99.1 BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) —ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach qu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Emplo

BioCryst Pharmaceuticals, Inc. Equity Award Retirement Policy, effective July 1, 2024

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. EQUITY AWARD RETIREMENT POLICY Effective Date: July 1, 2024 The Compensation Committee (the “Committee”) of the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) has determined that it is appropriate to adopt this policy (this “Policy”) to provide Covered Employees with continued vesting eligibility upon a termination of employment wit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-2318

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior gui

EXHIBIT 99.1 BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BCRX / BioCryst Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment

SC 13G/A 1 BioCrystPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOCRYST PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09058V103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome —Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the cli

EXHIBIT 99.1 BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome —Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from trial expected by end of 2025— RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceut

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

EXHIBIT 99.1 U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded BioCryst up to a $69 million contract for the procurement of up to 95,62

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 BioCryst Pharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (

As filed with the Securities and Exchange Commission on August 6, 2024

As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOC

BioCryst Pharmaceuticals, Inc. Equity Award Retirement Policy, effective July 1, 2024.

Exhibit 10.3 BIOCRYST PHARMACEUTICALS, INC. EQUITY AWARD RETIREMENT POLICY Effective Date: July 1, 2024 The Compensation Committee (the “Committee”) of the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) has determined that it is appropriate to adopt this policy (this “Policy”) to provide Covered Employees with continued vesting eligibility upon a termination of employment wit

Form of Notice of Performance-Based Restricted Stock Unit Award and Performance-Based Restricted Stock Unit Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.4 to the Company’s Form 10-Q filed

Exhibit 10.4 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD Notice is hereby given that BioCryst Pharmaceuticals, Inc. (the “Company”) has selected you to receive an award of performance-based restricted stock units with respect to the Company’s Common Stock (such award referred to herein as the “RSUs” or “Award”) as described below and

First Amendment to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective June 10, 2024.

Exhibit 10.2 FIRST AMENDMENT TO THE BIOCRYST PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY WHEREAS, BioCryst Pharmaceuticals, Inc. (the “Company”) maintains the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the “Policy”); and WHEREAS, pursuant to the Policy, the Board of Directors (the “Board”) of the Company may amend the Policy at any time in its sol

Filing Fee Table (filed herewith).

Calculation of Filing Fee Tables S-8 BIOCRYST PHARMACEUTICALS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update —Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400

EXHIBIT 99.1 BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update —Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipelin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 22, 2024). Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed June 13, 2024.

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 22, 2024)   Article One GENERAL PROVISIONS I.                   PURPOSES OF THE PLAN A.                This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,” is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIO

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidan

EXHIBIT 99.1 BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical tri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 BioCryst Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def

BioCryst Pharmaceuticals, Inc. Rule 10D-1 Clawback Policy. Incorporated by reference to Exhibit 97 to the Company’s Form 10-K filed on February 27, 2024.

Exhibit 97 BioCryst Pharmaceuticals, Inc. RULE 10D-1 CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of BioCryst Pharmaceuticals, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements (including any such correction that is material to the previously issued financial statements, or that

BIOCRYST PHARMACEUTICALS, INC. Debt Securities Dated as of [___] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture

Exhibit 4.8 EXECUTION VERSION BIOCRYST PHARMACEUTICALS, INC. Debt Securities Indenture Dated as of [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PH

securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to

Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

As filed with the Securities and Exchange Commission on February 27, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 27, 2024 Registration No.

Calculation of Filing Fee Tables Form S-3 (Form Type) BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioCryst Pharmaceuticals, Inc.

Subsidiaries of the Registrant.

Exhibit 21 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation BioCryst Canada, ULC British Columbia BioCryst España S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between

EXHIBIT 99.1 BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025— RESEARCH TRIAN

BCRX / BioCryst Pharmaceuticals, Inc. / Avoro Capital Advisors LLC - BIOCRYST PHARMACEUTICALS INC. Passive Investment

SC 13G 1 p24-0687sc13g.htm BIOCRYST PHARMACEUTICALS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioCryst Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 09058V103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check

BCRX / BioCryst Pharmaceuticals, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm242424d31sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 7)* BioCryst Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 09058V103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the

BCRX / BioCryst Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: BioCryst Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 09058V103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is

Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., effective January 16, 2024. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed January 18, 2024.

Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF BIOCRYST PHARMACEUTICALS, INC. Effective January 16, 2024 TABLE OF CONTENTS Page ARTICLE 1 – Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 3 1.9 Action at Meeting 3 1.10 Nominations and Other Stockholder Business. 3 ARTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Empl

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —OR

EXHIBIT 99.1 BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Emp

As filed with the Securities and Exchange Commission on November 8, 2023

As filed with the Securities and Exchange Commission on November 8, 2023 Registration No.

BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (as amended and restated

Exhibit 10.2 BIOCRYST PHARMACEUTICALS, INC. INDUCEMENT EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF OCTOBER 26, 2023) ARTICLE ONE GENERAL PROVISIONS I.PURPOSES OF THE PLAN A.This Inducement Equity Incentive Plan (as amended and restated, the “Plan”) is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), by providing a method whereby

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BIOCRYST PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

EXHIBIT 99.1 BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome — entering clinic in 2H 2024 Bifunctional fusion protein enabling simultaneous inhibi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector® – SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –

EXHIBIT 99.1 BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector® – SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) - BioC

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update - Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and

EXHIBIT 99.1 BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update - Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) - - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue - - Net cash utilization of $16.5 million in Q3 2023 (-43.9 percent y-o-y) - - Company to host R&D Day

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

EXHIBIT 99.1 BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013 RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Facto

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOC

BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of July 7, 2023).

Exhibit 10.3 BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED AS OF JULY 7, 2023) I.PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of BioCryst Pharmaceuticals, Inc. by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through participation in a payroll deduction base

Loan Agreement, dated as of April 17, 2023, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors signatory thereto or otherwise party thereto from time to time, BioPharma Credit PLC, as collateral agent for the lenders, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, as lenders. Incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed on August 7, 2023.

Exhibit 10.1 Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked “[***]” has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. THE TERM L

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update — Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak OR

EXHIBIT 99.1 BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update — Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS of ($0.40), non-GAAP EPS of ($0.24), excluding one-time debt extinguishment fee of $29 million— — BCX1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BIOCRYST PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on June 30, 2023

As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 BioCryst Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 24, 2023). Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed June 14, 2023.

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 24, 2023) Article One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,” is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), by provi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 BioCryst Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commiss

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update —Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, inc

EXHIBIT 99.1 BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update —Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth q-o-q— —Over 1,000 U.S. patients on ORLADEYO therapy— —ORLADEYO net revenue in 2023 expected to be no less th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

EXHIBIT 99.1 BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP. BioCryst has elected to draw $300 million of the $450 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 BioCryst Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer o

Subsidiaries of the Registrant.

Exhibit 21 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation BioCryst Canada, ULC British Columbia BioCryst España S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PH

Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the BioCryst Pharmaceuticals, Inc.

Exhibit 10.25 BIOCRYST PHARMACEUTICALS, INC. INDUCEMENT EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Notice is hereby given that BioCryst Pharmaceuticals, Inc. (the “Company”) has selected you to receive an award of restricted stock units with respect to the Company’s Common Stock (such award referred to herein as the “RSUs” or “Award”) as described below and granted pursuant to the

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million

EXHIBIT 99.1 BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— —ORLADEYO peak sales expected to be $1 billion— RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals

BCRX / BioCryst Pharmaceuticals, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm234999d27sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 6)* BioCryst Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 09058V103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the

BCRX / BioCryst Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0412-biocrystpharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: BioCryst Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 09058V103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance —ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenu

EXHIBIT 99.1 BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance —ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in 2023— —Company expects ORLADEYO peak sales of $1 billion— RESEARCH TRIANGLE PARK, N.C., Jan

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases —Company also expanding its discovery platform in complement-mediated diseases, including p

EXHIBIT 99.2 BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases —Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, I

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

EXHIBIT 99.1 BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013 RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer beli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 BioCryst Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

Amendment No. 1 to the Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan, dated September 15, 2022.

Exhibit 10.4 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this ?Amendment?), dated this 15th day of September 2022 (the "Effective Date"), is entered into by and between BioCryst Pharmaceuticals, Inc. (the ?Company?) and Dr. William Sheridan (?Employee?). RECITALS WHEREAS, the Company and Employee are parties to tha

Amendment Number Two to Credit Agreement, dated as of August 3, 2022, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors listed on the signature pages thereto, the lenders listed on the signature pages thereto, and Athyrium Opportunities III Co-Invest 1 LP, as administrative agent for the lender. Incorporated by reference to Exhibit 10.2 of the Company’s Form 10-Q filed November 4, 2022.

Exhibit 10.2 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NUMBER TWO TO CREDIT AGREEMENT THIS AMENDMENT NUMBER TWO TO CREDIT AGREEMENT (this ?Amendment?), dated as of August 3, 2022, is entered into by and among BIOCRYST PHARMACEUTICALS, INC.

Waiver to Credit Agreement, dated as of July 14, 2022, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors listed on the signature pages thereto, the lenders listed on the signature pages thereto, and Athyrium Opportunities III Co-Invest 1 LP, as administrative agent for the lenders.

Exhibit 10.1 WAIVER THIS WAIVER (this ?Waiver?), dated as of July 14, 2022, is entered into by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (the ?Borrower?), the guarantors listed on the signature pages hereto (the ?Guarantors?), the lenders listed on the signature pages hereto (such lenders, and the other lenders party to the Credit Agreement (as defined below), together with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 BioCryst Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones —$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021— —Underlying patient trends remain strong with nine percent paid pati

EXHIBIT 99.1 BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones ?$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021? ?Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022? ?Company expands complement pipeline by advancing second oral Factor D inhibitor, BCX10013, into clinical developm

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

EXHIBIT 99.1 BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company?s significant pipeline of development candidates. Dr. Ryan Arnold

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BIOCRYST PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on August 31, 2022

As filed with the Securities and Exchange Commission on August 31, 2022 Registration No.

BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (as amended and restated August 31, 2022). Incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 (File No. 333-267193) filed August 31, 2022.

Exhibit 99.1 BIOCRYST PHARMACEUTICALS, INC. INDUCEMENT EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF AUGUST 31, 2022) Article One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Inducement Equity Incentive Plan (as amended and restated, the ?Plan?) is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), by providing a method whereby

Amendment, dated August 10, 2022, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services

EXHIBIT 10.1

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

EXHIBIT 99.1 U.S. Government Exercises Option to Purchase Additional RAPIVAB? (peramivir injection) from BioCryst for Pandemic Influenza Preparedness RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses o

Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 29, 2022.

John E. Outen -S Digitally signed by John E. Outen -S Date: 2022.06.29 13:59:55 -04'00' Exhibit 10.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOC

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.4 to the Company’s Form 10-Q filed August 5, 2022.

Exhibit 10.4 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF GRANT OF NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AWARD Notice is hereby given of the following grant of restricted stock units with respect to the Company?s Common Stock (such award referred to herein as the ?Award?) pursuant to the Director Grant Program in effect under the BioCryst Pharmaceuticals, Inc. Stock Incentiv

Form of Notice of Grant of Non-Employee Director Stock Option and Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.3 to the Company’s 10-Q filed August 5, 2022.

Exhibit 10.3 BIOCRYST PHARMACEUTICALS, INC. NOTICE OF GRANT OF NON-EMPLOYEE DIRECTOR STOCK OPTION Notice is hereby given of the following stock option grant (the ?Option?) to purchase shares of the Common Stock of BioCryst Pharmaceuticals, Inc. (the ?Company?) pursuant to the Director Grant Program in effect under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (the ?Plan?): Optionee: Gran

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones —Q2 2022 ORLADEYO net revenue of $65.2 million— —FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million—

EXHIBIT 99.1 BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones —Q2 2022 ORLADEYO net revenue of $65.2 million— —FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended Ju

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BIOCRYST PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on July 14, 2022

As filed with the Securities and Exchange Commission on July 14, 2022 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 18, 2022). Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed June 7, 2022.

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 18, 2022) Article One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Stock Incentive Plan (the ?Plan?), formerly the ?BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,? is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), by provi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 ny20004344x1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted

BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective April 18, 2022. Incorporated by reference to Exhibit 10.2 to the Company’s Form 10-Q filed May 9, 2022.

Exhibit 10.2 BIOCRYST PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective April 18, 2022 Each member of the Board of Directors (the ?Board?) of BioCryst Pharmaceuticals Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each a ?Director?) will, automatically and without further action by the Board or the Compensation Committ

Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 30, 2022.

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACEUTIC

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commiss

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones —Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on BCX9930 investigatio

EXHIBIT 99.1 BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones ?Q1 2022 ORLADEYO net revenue of $49.7 million? ?ORLADEYO net revenue in 2022 expected to be no less than $250 million? ?Company provides update on BCX9930 investigation? RESEARCH TRIANGLE PARK, N.C., May 05, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy St

Definitive Proxy Statement on Schedule 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

EXHIBIT 99.1 BioCryst Pauses Enrollment in BCX9930 Clinical Trials RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients. During the investigation, the company will not en

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

Purchase and Sale Agreement, dated as of November 19, 2021, between BioCryst Pharmaceuticals, Inc. and OCM IP Healthcare Holdings Limited.

Exhibit 10.103 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked ?[***]? has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Purchase

Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

Exhibit 10.14 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Notice is hereby given that BioCryst Pharmaceuticals, Inc. (the ?Company?) has selected you to receive an award of restricted stock units with respect to the Company?s Common Stock (such award referred to herein as the ?RSUs? or ?Award?) as described below and granted pursuant to the BioCryst Ph

Common Stock Purchase Agreement, dated as of November 19, 2021, between BioCryst Pharmaceuticals, Inc. and RPI Intermediate Finance Trust.

Exhibit 10.104 Certain personally identifiable information has been omitted from this exhibit in places marked ?[***]? pursuant to Item 601(a)(6) under Regulation S-K. BIOCRYST PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (this ?Agreement?) is made as of November 19, 2021 by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Compa

Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 27, 2021.

Exhibit 10.76

Purchase and Sale Agreement, dated as of November 19, 2021, between BioCryst Pharmaceuticals, Inc. and RPI 2019 Intermediate Finance Trust.

Exhibit 10.102 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked ?[***]? has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. 2021 Pur

Amendment Number One to Credit Agreement, dated as of November 19, 2021, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors listed on the signature pages thereto, the lenders listed on the signature pages thereto, and Athyrium Opportunities III Co-Invest 1 LP, as administrative agent for the lenders.

Exhibit 10.101 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked ?[***]? has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. AMENDMEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC

Amendment #26 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 27, 2021.

Exhibit 10.72

Subsidiaries of the Registrant.

Exhibit 21 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation JPR Royalty Sub, LLC Delaware BioCryst US Sales Co., LLC Delaware BioCryst UK Limited England and Wales BioCryst Ireland Limited Ireland BioCryst Pharma Deutschland GmbH Germany BioCryst France SAS France

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones — Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million

EXHIBIT 99.1 BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones — Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients — RESEARCH TRIANGLE PARK, N.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases

EXHIBIT 99.1 BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, i

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employe

BCRX / BioCryst Pharmaceuticals, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

BCRX / BioCryst Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: BioCryst Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 09058V103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst Appoints Machelle Sanders to Board of Directors

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 BioCryst Appoints Machelle Sanders to Board of Directors RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and accomplished pharmaceutical operations executive, Machelle Sanders, to its board of directors. Ms.

2

VIA EDGAR January 14, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Kristin Lochhead and Brian Cascio Re: BioCryst Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 000-23186 Dear Ladies and Gentlemen: On behalf of BioCryst Pharmaceuticals, I

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance —ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021— —

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance —ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021— —ORLADEYO net revenue expected to more than double in 2022 to no less than $250 million; Company expect

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

EXHIBIT 99.1 BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal noc

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

EXHIBIT 99.1 BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal noc

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (C

Amendment #25 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 15, 2021.

Exhibit 10.7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACE

Amendment No. 1 to the Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Charles Gayer, dated September 24, 2021. Incorporated by reference to Exhibit 10.10 to the Company’s Form 10-Q filed November 4, 2021.

Exhibit 10.10 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?), dated this 24th day of September 2021 (the "Effective Date"), is entered into by and between BioCryst Pharmaceuticals, Inc. (the ?Company?) and Mr. Charles Gayer ( ?Employee?). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of January

Amendment No. 1 to the Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Anthony Doyle, dated September 24, 2021. Incorporated by reference to Exhibit 10.8 to the Company’s Form 10-Q filed November 4, 2021.

Exhibit 10.8 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?), dated this 24th day of September 2021 (the "Effective Date"), is entered into by and between BioCryst Pharmaceuticals, Inc. (the ?Company?) and Mr. Anthony Doyle ( ?Employee?). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of March 29

Amendment No. 1 to the Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Dr. Helen M. Thackray, dated September 24, 2021. Incorporated by reference to Exhibit 10.9 to the Company’s Form 10-Q filed November 4, 2021.

Exhibit 10.9 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?), dated this 24th day of September 2021 (the "Effective Date"), is entered into by and between BioCryst Pharmaceuticals, Inc. (the ?Company?) and Dr. Helen Thackray ( ?Employee?). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of Februar

BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones —3Q 2021 revenue of $41.0 million— —ORLADEYO® (berotralstat) net revenue of $37.0 million— —Full year 2021 ORLADEYO net revenue expected to be $115-$120 million—

EXHIBIT 99.1 BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones ?3Q 2021 revenue of $41.0 million? ?ORLADEYO? (berotralstat) net revenue of $37.0 million? ?Full year 2021 ORLADEYO net revenue expected to be $115-$120 million? RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results f

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Co

As filed with the Securities and Exchange Commission on September 30, 2021

As filed with the Securities and Exchange Commission on September 30, 2021 Registration No.

BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (as amended and restated July 23, 2021). Incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 (File No. 333-259919) filed September 30, 2021.

Exhibit 99.1 BIOCRYST PHARMACEUTICALS, INC. INDUCEMENT EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF JULY 23, 2021) Article One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Inducement Equity Incentive Plan (as amended and restated, the ?Plan?) is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), by providing a method whereby c

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (

BioCryst Appoints Dr. Amy McKee to Board of Directors

EXHIBIT 99.1 BioCryst Appoints Dr. Amy McKee to Board of Directors RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), Amy McKee, M.D., to its board of director

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile

EXHIBIT 99.1 U.S. Government Exercises Option to Purchase Additional RAPIVAB? (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,0

Amendment #4, dated August 27, 2021, to the Contract dated September 1, 2018, between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed September 1, 2021.

Exhibit 10.1

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

BioCryst Appoints Dr. Steven Galson to Board of Directors

EXHIBIT 99.1 BioCryst Appoints Dr. Steven Galson to Board of Directors RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former acting surgeon general, Steven Galson, M.D., MPH to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 BioCryst Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Com

Per share

TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes, dated August 4, 2021. Incorporated by reference to Exhibit 10.6 to the Company’s Form 10-Q filed August 9, 2021.

Exhibit 10.6 August 4, 2021 Mrs. Alane Barnes [email protected] Dear Ms. Barnes: As part of our review of the terms of our employment agreements with our executives and our intentions to align the terms of such agreements so that they are generally consistent with one another, this letter agreement (the ?Agreement?) amends and restates the employment letter agreement, dated August 2, 2013, as a

Separation Agreement and Release between BioCryst Pharmaceuticals, Inc. and Megan Sniecinski, dated August 8, 2021. Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed August 9, 2021.

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Megan Sniecinski (?Employee?) and BioCryst Pharmaceuticals, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee is currently the Company?s Chief Business Officer and is employed by the Company and/

Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu, dated August 4

Exhibit 10.5 August 4, 2021 Dr. Y.S. Babu [email protected] Dear Dr. Babu: As part of our review of the terms of our employment agreements with our executives and our intentions to align the terms of such agreements so that they are generally consistent with one another, this letter agreement (the ?Agreement?) amends and restates the employment letter agreement, dated April 27, 2012, as amended No

Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 29, 2021.

Exhibit 10.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACEUTICA

Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan, dated August 4, 2021. Incorporated by reference to Exhibit 10.4 to the Company's Form 10-Q filed August 9, 2021.

Exhibit 10.4 August 4, 2021 Dr. William Sheridan [email protected] Dear Dr. Sheridan: As part of our review of the terms of our employment agreements with our executives and our intentions to align the terms of such agreements so that they are generally consistent with one another, this letter agreement (the ?Agreement?) amends and restates the employment letter agreement, dated June 12, 2008

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer o

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones —2Q 2021 revenue of $50.0 million— —ORLADEYO® (berotralstat) net revenue of $28.5 million—

EXHIBIT 99.1 BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones ?2Q 2021 revenue of $50.0 million? ?ORLADEYO? (berotralstat) net revenue of $28.5 million? RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021, and provided a corporate up

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Appoints Vincent Milano to Board of Directors

EXHIBIT 99.1 BioCryst Appoints Vincent Milano to Board of Directors RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors. Mr. Milano currently serves as chief executive officer of Idera Pharmace

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commis

BioCryst Launches ORLADEYO™ (berotralstat) in Germany

EXHIBIT 99.1 BioCryst Launches ORLADEYO? (berotralstat) in Germany RESEARCH TRIANGLE PARK, N.C., June 03, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO? (berotralstat) is now available for patients with a prescription in Germany. ORLADEYO was approved by the European Medicines Agency (EMA) on April 30, 2021 for the prevention o

As filed with the Securities and Exchange Commission on May 28, 2021

As filed with the Securities and Exchange Commission on May 28, 2021 Registration No.

As filed with the Securities and Exchange Commission on May 28, 2021

As filed with the Securities and Exchange Commission on May 28, 2021 Registration No.

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated April 1, 2021). Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed May 26, 2021.

Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 1, 2021) Article One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Stock Incentive Plan (the ?Plan?), formerly the ?BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,? is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), by provid

BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated April 1, 2021). Incorporated by reference to Exhibit 10.2 to the Company's Form 8-K filed May 26, 2021.

Exhibit 10.2 BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED AS OF APRIL 1, 2021) I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of BioCryst Pharmaceuticals, Inc. by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through participation in a payroll deduction ba

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer of

BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

EXHIBIT 99.1 BioCryst Receives UK Approval of ORLADEYO? (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom?s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commis

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACEUTIC

Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Dr. Helen M. Thackray, dated February 18, 2021. Incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed May 7, 2021.

Exhibit 10.1 February 18, 2021 Helen Thackray, MD 7200 Pyle Road Bethesda, MD 20817 Dear Dr. Thackray: On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), we are pleased to offer you the position of Chief Research & Development Officer. You will report directly to Jon Stonehouse, President & CEO. We, along with the other members of the Company?s Board of Directors

Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.2 to the Company’s Form 10-Q filed May 7, 2021.

Exhibit 10.2 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Notice is hereby given that BioCryst Pharmaceuticals, Inc. (the ?Company?) has selected you to receive an award of restricted stock units with respect to the Company?s Common Stock (such award referred to herein as the ?RSUs? or ?Award?) as described below and granted pursuant to the BioCryst Pha

BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones —Q1 2021 ORLADEYO™ (berotralstat) net revenue of $10.9 million— —ORLADEYO now approved in U.S., Japan and EU— —BioCryst reaches agreement with FDA that change from base

EXHIBIT 99.1 BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones ?Q1 2021 ORLADEYO? (berotralstat) net revenue of $10.9 million? ?ORLADEYO now approved in U.S., Japan and EU? ?BioCryst reaches agreement with FDA that change from baseline in hemoglobin is the primary endpoint for pivotal PNH trials of oral BCX9930 set to begin in second half of 2021? RESEARCH TRIANGLE

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commiss

BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

EXHIBIT 99.1 BioCryst Receives European Commission Approval of ORLADEYO? (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO? (berotralstat) for the prev

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 14, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commissi

BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema —ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price listing triggers $15

EXHIBIT 99.1 BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema —ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price listing triggers $15 million milestone payment to BioCryst— RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Na

Definitive Proxy Statement on Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer o

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Comm

BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 ina

EXHIBIT 99.1 BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— —Mean hemoglobin increased from 8.3 g/dL to 11.8 g/dL in treatment-naïve patients and fr

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 BioCryst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction (Commission (IRS Employer o

BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23186 62-1413174 (State or Other Jurisdiction of Incorporation) (Commi

License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005.

Exhibit 10.32 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED ?[***]? BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LICENSE AGREEMENT BETWEEN ALBERT EINSTEIN COLLEGE OF MEDICINE, INDUSTRIAL RESEARCH, LTD AND BIOCRYST PHARMACEUTICALS, INC. Statement 1 1. Definitions 2 1.01 ?Field? 2 1.02 ?Agreement Patents? 2

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC

Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Charles Gayer, dated January 14, 2020. Incorporated by reference to Exhibit 10.26 to the Company’s Form 10-K filed March 1, 2021.

Exhibit 10.26 January 14, 2020 Charles Gayer 711 Watts Street Durham, NC 27701 Dear Charlie: On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), we are pleased to offer you the position of Chief Commercial Officer. We, along with the other members of the Company?s Board of Directors (the ?Board?), and the Company?s management team, are all very impressed with what

Subsidiaries of the Registrant.

Exhibit 21 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation JPR Royalty Sub, LLC Delaware BioCryst US Sales Co., LLC Delaware BioCryst UK Limited England and Wales BioCryst Ireland Limited Ireland BioCryst Pharma Deutschland GmbH Germany BioCryst France SAS France